New drug targets Hard-to-Treat cancers in early trial
NCT ID NCT06414460
First seen Nov 05, 2025 · Last updated May 15, 2026 · Updated 22 times
Summary
This study tests a new experimental drug called ISM3412 in about 80 adults with advanced solid tumors that have a specific genetic change (MTAP deletion) and have stopped responding to standard treatments. The main goals are to check the drug's safety and find the best dose. The study has two parts: first, increasing doses to see how much is safe, and then testing that dose more closely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED/METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, China
-
Community Cancer Center North
RECRUITINGIndianapolis, Indiana, 46250-2042, United States
-
Jiangsu Provincial People's Hospital
RECRUITINGNanjing, Jiangsu, China
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
-
Sarah Cannon Research Institute at HealthONE
RECRUITINGDenver, Colorado, 80218, United States
-
Shanghai Gobroad Cancer Hospital
RECRUITINGShanghai, Shanghai Municipality, China
-
Smilow Cancer Hospital at Yale New Haven Breast Center
RECRUITINGNew Haven, Connecticut, 06520-8028, United States
Contact
-
Sun Yat-sen university cancer center
RECRUITINGGuangzhou, Guangdong, 510030, China
Contact
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030-4095, United States
Conditions
Explore the condition pages connected to this study.